Current criteria to predict low-risk prostate cancer (PCa) are still subject to discussion as a substantial number of PCa patients who progress to a more aggressive disease seem to be missed, using these criteria.
The main challenge in PCa diagnosis, therefore, is to distinguish patients with low-risk PCa who will show slow progression of disease from patients at risk for progression to a more aggressive cancer. The current discovered biomarkers could potentially guide in this management and improve detection, staging, and prognosis. This paper provides an overview of the current available serum-, urine-, and tissue-based biomarkers in PCa and evaluates the clinical usefulness of these biomarkers in the detection and management of low-risk PCa.
Written by:
Dijkstra S, Hamid AR, Leyten GH, Schalken JA. Are you the author?
Department of Urology, Radboud University Nijmegen Medical Centre, Geert-Grooteplein Zuid 10, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Reference: Prostate Cancer. 2012;2012:327104.
doi: 10.1155/2012/327104
PubMed Abstract
PMID: 23304520
UroToday.com Prostate Cancer Section
